Richard,
<After all, two great earnings blowouts haven't been able to get us past the low 30's.>
Milestone payments, although spendable funds, dont affect price as much as if the same amount were from product sales because it is non-recurring. Conversely, non-recurring losses dont hurt a company as much either. Unigen, a small bio-med co., short on cash, no sales yet, just got a significant milestone payment--part of an eventual total of $50MM in payments from Warner Lambert and the stock went down. Similar to VVUS, it has a potential blockbuster drug, but no sales yet. Milestone payments seem to receive a ho-hum from the market.
<...the 30's might be a thing of the past by late September.>
Guess VVUS better get on truckin' down the hill if it's going to 18 before climbing back to over $40--all within 6 weeks.<ggg> You're already making me feel like I oughta retract that 18 target and the day isn't over yet!! Naw, the hoots would probably be worse if I retracted/revised it than if I just left it. Dont want to vie with Tuna for Clinton's flip-flop trophy.<hell, whole paragraph is ggg>
Thanks for the response. |
